Intellia Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Intellia Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTLA

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. 

CEO
John M. Leonard
CEOJohn M. Leonard
Employees
377
Employees377
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2014
Founded2014
Employees
377
Employees377

NTLA Key Statistics

Market cap
1.66B
Market cap1.66B
Price-Earnings ratio
-3.36
Price-Earnings ratio-3.36
Dividend yield
Dividend yield
Average volume
5.04M
Average volume5.04M
High today
$12.85
High today$12.85
Low today
$11.65
Low today$11.65
Open price
$12.43
Open price$12.43
Volume
6.53M
Volume6.53M
52 Week high
$28.25
52 Week high$28.25
52 Week low
$7.95
52 Week low$7.95

Stock Snapshot

Intellia Therapeutics(NTLA) stock is priced at $11.92, giving the company a market capitalization of 1.66B. It carries a P/E multiple of -3.36.

On 2026-07-17, Intellia Therapeutics(NTLA) stock traded between a low of $11.65 and a high of $12.85. Shares are currently priced at $11.92, which is +2.3% above the low and -7.2% below the high.

Intellia Therapeutics(NTLA) shares are trading with a volume of 6.53M, against a daily average of 5.04M.

During the past year, Intellia Therapeutics(NTLA) stock moved between $7.95 at its lowest and $28.25 at its peak.

During the past year, Intellia Therapeutics(NTLA) stock moved between $7.95 at its lowest and $28.25 at its peak.

NTLA News

Simply Wall St 11h
Intellia Therapeutics Resumes Key Trials, Is The Undervalued Case Still Convincing?

The FDA’s decision to lift clinical holds on Intellia Therapeutics (NTLA)’s MAGNITUDE and MAGNITUDE-2 trials has refocused attention on the stock, as patient en...

Intellia Therapeutics Resumes Key Trials, Is The Undervalued Case Still Convincing?
TipRanks 1d
Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research

Wolfe Research analyst Andy Chen downgraded Intellia Therapeutics (NTLA) to Underperform from Peer Perform with a $9 price target The firm said its primary conc...

TipRanks 6d
BlackBerry, Sony, Sunrun, Credo, Intellia: Insider Sell-Off Shock

Insiders have been trading these 5 stocks: ((TSE:BB)), ((SONY)), ((RUN)), ((CRDO)) and ((NTLA)). Here is a breakdown of their recent trades and their value. Bl...

Analyst ratings

50%

of 20 ratings
Buy
50%
Hold
35%
Sell
15%

More NTLA News

TipRanks 7d
Intellia Therapeutics price target raised to $17 from $12 at Wedbush

Wedbush raised the firm’s price target on Intellia Therapeutics to $17 from $12 and keeps a Neutral rating on the shares. Relevant to Intellia Therapeutics (NTL...

People also own

Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.